Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

McKesson Corporation
MCK - NYSE - $1060.84 (as of ) ▼ -1.04%
-
Earnings Wed 3 Feb

McKesson opens the
books on Wednesday evening.

The median of 6 price targets is $9891, stock is $1061, -6.8% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
C+
Council 1/6 - Historical V1 score 40

C+ — FMP rating1.

Quick Answer

Q3 consensus: revenue $113.6B1, EPS $10.941. Britt Vitalone guided North American Pharmaceutical to 14.5-18.5% (previous 35%) in the Q4 earnings call2. 7 consecutive quarters of beat1.

$10.94 EPS Estimate Last year $9.34 - +17% YoY
18.5% North American Pharmaceutical Guidance Previous quarter was 35%
7 Beat Streak Expectations beaten consecutively for the last 7 quarters

Q2 FY27 EPS $11.68 vs $10.72 estimate: beat (+9.0%)1. Stock move on the next trading day: +0.2%1.

Next report

What to watch in Q3 FY27 (Feb 3, 2027)

  • EPS: consensus $10.94, against $9.34 in the same quarter a year ago (+17%).
  • Revenue: consensus $113.6B.

Watchlist

6 metrics stand out this quarter.

$43.80 Expectation / Guide

Fy27 Eps Guidance

McKesson guided FY27 adjusted EPS to $43.80-$44.60, implying 12% to 14% year-over-year growth.

"For fiscal 2027, we're establishing an adjusted earnings per diluted share guidance range of $43.80 to $44.60, representing 12% to 14% year-over-year growth."

- Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
35% Investor Focus

Oncology Multispecialty Growth

Oncology and multispecialty revenue rose 35% to $12.7 billion in Q4, driven by provider growth, specialty distribution and acquisitions.

Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
$1.25 billion Investor Focus

Medsurg Apollo Separation

McKesson agreed to sell an approximately 13% minority stake in Medical-Surgical Solutions to Apollo Funds for $1.25 billion, valuing the business at roughly $13 billion of enterprise value.

Brian Tyler, CEO - Q4 FY26 Earnings Call - May 7, 2026
$14 billion Investor Focus

Glp1 Distribution

GLP-1 distribution revenue reached $14 billion in Q4, up 22% year over year but down 4% sequentially.

"GLP-1 distribution revenues reached $14 billion in the quarter, an increase of $2 billion or 22% compared to the prior year. However, revenues declined 4% sequentially."

- Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
double-digit Investor Focus

Ira Branded Price Impact

Branded pharmaceutical price changes under the Inflation Reduction Act weighed on revenue growth, but adjusted segment operating profit still grew double digits in fiscal '26.

Brian Tyler, CEO - Q4 FY26 Earnings Call - May 7, 2026
$5 billion Investor Focus

Fy27 Share Repurchases

McKesson plans to repurchase approximately $5 billion of shares in fiscal 2027.

Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 1 / 6 Bullish

6 investor frameworks. 1 bullish (Ken Griffin), 3 bearish (Jim Simons, Klarman, Munger), 2 neutral (Ray Dalio, Buffett).

How is it calculated? ->
Ray Dalio macro - target upside -6.8%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 70
Klarman value - target upside -6.8%
Buffett quality - ROE score 1/5
Munger valuation - target upside -6.8%
Munger's Mindset character & balance sheet lens
Overvalued

Quality business, but price is high.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
70.2 RSI 70.2 overbought, 50d above
MACD
+13.10 price above 50d - support positive
50d MA
$938 stock 13.1% above - short-term support
200d MA
$868 stock 22.2% above - long-term support
Volume (10d)
+1% increase - pre-earnings positioning
Resistance
$989
Analyst median target - upgrade trigger if broken
Current
$1061
Pre-earnings position
Support
$738
Invalidation - close below this is a technical breakdown
Pattern
Range
$738-$989 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q3 FY26
$9.34 vs $9.17 est · Next-day price move: +16.5%
BEAT
Q4 FY26
$11.69 vs $11.56 est · Next-day price move: -2.5%
BEAT
Q1 FY27
$9.93 vs $9.56 est · Next-day price move: -0.7%
BEAT
Q2 FY27
$11.68 vs $10.72 est · Next-day price move: +0.2%

Q2 FY27 (November 4, 2026) EPS $11.68 vs $10.72 estimate: beat (+9.0%)1.

Three scenarios: what could happen?

North American Pharmaceutical below 35%

"In the oncology and multispecialty segment, we anticipate revenue growth of 14.5% to 18.5% and operating profit growth of 13.5% to 17.5%."

- Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

Insider trading signal

Form 4 Q2 FY27: 6 transactions, net -$9.23M1.

Executive Action Amount Date
Fraga Francisco EVP, CIO and CTO Sale -$716.9K 2026-11-06
Fraga Francisco EVP, CIO and CTO Sale -$630.0K 2026-11-05
Fraga Francisco EVP, CIO and CTO Sale -$797.1K 2026-10-19
Rutledge Napoleon B JR SVP, Controller & CAO Sale -$99.0K 2026-09-10
Lerman Bradley E director Sale -$268.6K 2026-08-11
TYLER BRIAN S. director, Chief Executive Officer Sale -$6.72M 2026-07-08

6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $123.7B market cap.

CapEx shock

Q4 CapEx $123.0M1. Q4 op margin 1.4%1 - this level in Q3 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q3 EPS > $10.94 + North American Pharmaceutical >= 18.5%
Threshold: EPS > $10.941 and North American Pharmaceutical >= 18.5%2.
Target: Break above median target $9891; high target $12001 upper bound.
Scenario B - In-Line
EPS approx $10.94 + North American Pharmaceutical 14.5-18.5%
Threshold: EPS approx $10.941, North American Pharmaceutical 14.5-18.5%, Q3 CapEx < $123.0M1.
Target: Consolidation in the band between current $10611 and median $9891.
Scenario C - Miss
EPS < $10.61 or North American Pharmaceutical < 35% or CapEx >= $123.0M
Threshold: EPS < $10.611 or North American Pharmaceutical < 35%2.
Current price $1061 — above SMA200 $8681.

Market Outlook

What do analysts say? 6 price targets · 16 ratings

Wall Street Consensus
$989
12-month median target price (-6.8% gap to the analyst consensus median)
13
BUY
3
HOLD
0
SELL
Risk Management
$738
Invalidation level - critical support threshold
$938 - 50-day MA (above, +13.1%)
$868 - 200-day MA (above, +22.2%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - MCK Q3 FY27
C+

You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Wednesday evening. The framework is ready on this page: Q3 EPS threshold $10.941, North American Pharmaceutical guidance 14.5-18.5%2, CapEx threshold "below $123.0M". Three anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Feb 3, 2027EARNINGSQ3 FY27 results (after market close) + earnings call
Feb 4, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Feb 9, 2027 – Feb 14, 2027FILING10-Q due within 40–45 days of quarter end (by Feb 9, 2027 – Feb 14, 2027); the exact deadline depends on filer status
~May 6, 2027EARNINGSQ4 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the MCK Q3 FY27 earnings preview cover?

This McKesson Corporation (MCK) Q3 FY27 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in MCK Q3 FY27 earnings?

McKesson Corporation (MCK): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

McKesson Corporation (MCK): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

McKesson Corporation (MCK): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded